Investors

Investors2018-11-26T12:55:12+00:00

Series A

Seed Investors

Coleman Fung
Coleman FungFounder
Feeling frustrated by traditional “silo” trading and risk management technologies as a derivatives trader, Coleman launched OpenLink in 1992 to challenge market conventions with a unique and open technology platform. As the initial business architect, he laid this cross-market risk architecture – which is still unique today – for a robust environment that seamlessly supports front- through back-office requirements for financial and energy/commodity markets. The company was chosen as the inaugural winner of Risk Management Innovator of the Year by Platts in 2007.
Richard Passov
Richard PassovFounder
Richard Passov has more than 25 years of leadership experience across technology and life science companies. He helped capitalize Sun Microsystems through its hyper-growth phase, leaving to join Intel where he became one of the first employees in Intel’s Venture Capital group. He helped steer Pfizer through $250 billion of acquisitions, strategic reviews of R&D productivity, the outsourcing of clinical trials and led the divestiture of Zoetis and it’s successful IPO. He’s on the board of OffAssignment, the Finance Comittee of OneAcreFund, and the Advisory Board for IEOR at UC Berkeley. He received a B.A. and M.B.A. from the University of California, Los Angelese along with an M.S., Operations Research from University of California, Berkeley.
Tim Opler, Ph.D.
Tim Opler, Ph.D.Founder
Tim has 24 years experience leading strategic and financial transactions across multiple sectors. He has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue. Before co-founding Torreya, Tim was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Tim was previously with Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch.

Discover The Future

Contact Us